Our Pipeline
We are programming biology to create optimal therapeutics for the greatest impact on human health.
| Program | Indication | Target | Modality | Phase | Collaborations | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | |||||||||
| Immunology & Inflammation | ||||||||||||
| GB-0895 | Severe Asthma | TSLP | Antibody |
Phase Phase 3 |
||||||||
| GB-0895 | TSLP |
Modality: monoclonal antibody How this investigational therapy could help: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. GB-0895 is an investigational antibody that binds and neutralizes TSLP to help reduce downstream inflammatory signaling in severe asthma. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. GB-0895 is currently being evaluated in Phase 3 clinical studies. |
||||||||||
| COPD | TSLP | Antibody |
Phase Phase 1 |
|||||||||
| GB-0895 | TSLP |
Modality: monoclonal antibody How this investigational therapy could help: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that contributes to airway inflammation and disease progression in COPD. GB-0895 is an investigational antibody designed to bind and neutralize TSLP, with the goal of reducing downstream inflammatory signaling in chronic airway disease. GB-0895 has been engineered for an extended half-life and is being evaluated in a Phase 1 clinical study in COPD to assess safety, pharmacokinetics, and pharmacodynamic activity. |
||||||||||
| Oncology | ||||||||||||
| GB-4362* | Various in combo with MMAE ADCs | Free MMAE | Antibody |
Phase Preclinical Completed |
||||||||
| GB-4362* | TSLP |
Modality: monoclonal antibody How this investigational therapy could help: GB-4362 is a monoclonal antibody designed to selectively bind free monomethyl auristatin E (MMAE). Free MMAE is associated with systemic toxicities when released from MMAE-based antibody-drug conjugates. GB-4362 is designed to reduce circulating free MMAE without interacting with intact ADCs. |
||||||||||
| GB-5267* | Metastatic Ovarian Cancer | MUC16 | Armored CAR T |
Phase Preclinical Completed |
Collaborations 
50/50
|
|||||||
| GB-5267* | Metastatic Ovarian Cancer |
Modality: CAR T-cell therapy How this investigational therapy could help: GB-5267 is an IL-18 armored CAR T-cell therapy targeting MUC16, a cell-surface antigen highly expressed in ovarian cancer. It is designed to redirect autologous T cells to recognize and kill MUC16-expressing tumor cells. The therapy is engineered to enhance T-cell activation, proliferation, and persistence within the tumor microenvironment. |
||||||||||
|
*IND "study may proceed" granted in December 2025 |
||||||||||||
Beyond the Clinical Stage Pipeline.
Multiple Other Innovative Preclinical Programs:
Leveraging the Generate Platform and its modular capabilities, we are advancing multiple innovative preclinical programs designed with differentiated characteristics beyond the reach of traditional technologies, including next-generation ADCs.
Platform Collaborations:
Six confidential collaboration programs, first announced in January 2022.
Multiple confidential collaboration programs, first announced in September 2024.
Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.